Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-01-23 am EST			5-day change	1st Jan Change
79.31 ^EUR	-0.56%		-1.82%	-4.12%

Jan. 23	European Stocks Trend Mostly Lower in Friday Trading; EU Suspends $109 Billion in Counter Tariffs Against US	MT
Jan. 23	SANOFI : JP Morgan remains Neutral	ZD

SANOFI : Receives a Buy rating from Jefferies

Published on 10/27/2025 at 05:22 am EDT

MarketScreener with dpa-AFX Analyser

SANOFI

-0.56%

Jefferies is positive on the stock with a Buy rating. Previously set at EUR 120, the target price is lowered to EUR 100.

Latest news about Sanofi

Jan. 23	European Stocks Trend Mostly Lower in Friday Trading; EU Suspends $109 Billion in Counter Tariffs Against US	MT
Jan. 23	SANOFI : JP Morgan remains Neutral	ZD
Jan. 23	SANOFI : Barclays remains Neutral	ZD
Jan. 23	SANOFI : Jefferies maintains a Buy rating	ZD
Jan. 23	Sanofi's Amlitelimab Confirms its Potential in Atopic Dermatitis	CI
Jan. 23	Diary - France corporate earnings week ahead	RE
Jan. 23	Sanofi to Proceed With Regulatory Submissions for Amlitelimab in Atopic Dermatitis	MT
Jan. 23	European Midday Briefing : Stocks Stall on Strained U.S.-Europe Relations	DJ
Jan. 23	JCDecaux, Sanofi, Sword Group... Stocks to Watch Today in Paris
Jan. 23	Sanofi Posts Positive Results from Late-stage Studies of Amlitelimab in Atopic Dermatitis	MT
Jan. 23	Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema	DJ
Jan. 23	Positive Data for Sanofi in Atopic Dermatitis
Jan. 23	Sanofi's amlitelimab confirms potential in atopic dermatitis	RE
Jan. 22	Escalate, De-Escalate, Repeat
Jan. 22	Europe's Key Companies – Telenor Jumps 8.1 Percent	FW
Jan. 22	SANOFI : Buy rating from Jefferies	ZD
Jan. 22	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality	RE
Jan. 21	Health Care Up After Trump Rescinds Tariff Threats - Health Care Roundup	DJ
Jan. 21	Sanofi Kept at Buy as Berenberg Highlights Drugmaker's Top-tier Topline, Deals Firepower	MT
Jan. 20	Global drugmakers rush to boost US presence as tariff threat looms	RE
Jan. 20	Novavax signs licensing agreement with Pfizer for vaccine development	RE
Jan. 16	Agomab Therapeutics files for US IPO - SEC filing	RE
Jan. 16	Arch Biopartners Inc. Announces Appointment of Patrick Vink as Chairman of the Board and Retirement of Claude Allary from the Board of Directors	CI
Jan. 16	UBS Downgrades Sanofi, Citing Lack of "Pipeline"
Jan. 16	SANOFI : UBS gives a Neutral rating	ZD

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2024, the group had 52 production sites worldwide. In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation. Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Employees

82,878

Sector

Pharmaceuticals

Calendar

Jan. 29 - Q4 2025 Earnings Release

More about the company